Mcl-1 is essential for the survival of plasma cells

Nature Immunology

Volumn 14, Issue 3, 2013, Pages 290-297

  Peperzak, Victor ^a,b   Vikström, Ingela ^a,b   Walker, Jennifer ^a,b   Glaser, Stefan P ^a,b   Lepage, Melanie ^c   Coquery, Christine M ^d   Erickson, Loren D ^d   Fairfax, Kirsten ^c   MacKay, Fabienne ^c   Strasser, Andreas ^a,b   Nutt, Stephen L ^a,b   Tarlinton, David M ^a,b  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL MATURATION ANTIGEN; B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; PROTEIN BCL 2; PROTEIN MCL 1;

ARTICLE; BONE MARROW; CELL DIFFERENTIATION; CELL SURVIVAL; CONTROLLED STUDY; GENE DELETION; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VIVO STUDY; PLASMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 85027921645     PISSN: 15292908     EISSN: 15292916     Source Type: Journal    
DOI: 10.1038/ni.2527     Document Type: Article

References (50)

1. Shaffer, A.L. et al. Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity 17, 51-62 (2002).
2. Shapiro-Shelef, M. et al. Blimp-1 is required for the formation of immunoglobulin secreting plasma cells and pre-plasma memory B cells. Immunity 19, 607-620 (2003).
3. Kallies, A. et al. Initiation of plasma-cell differentiation is independent of the transcription factor Blimp-1. Immunity 26, 555-566 (2007).
4. Kallies, A. et al. Plasma cell ontogeny defined by quantitative changes in Blimp-1 expression. J. Exp. Med. 200, 967-977 (2004).
5. Sze, D.M., Toellner, K.M., Garcia de Vinuesa, C., Taylor, D.R. & MacLennan, I.C. Intrinsic constraint on plasmablast growth and extrinsic limits of plasma cell survival. J. Exp. Med. 192, 813-821 (2000).
6. Tarlinton, D. B-cell memory: are subsets necessary? Nat. Rev. Immunol. 6, 785-790 (2006).
7. Rajewsky, K. Clonal selection and learning in the antibody system. Nature 381, 751-758 (1996).
8. Kabashima, K. et al. Plasma cell S1P1 expression determines secondary lymphoid organ retention versus bone marrow tropism. J. Exp. Med. 203, 2683-2690 (2006).
9. Tarlinton, D., Radbruch, A., Hiepe, F. & Dorner, T. Plasma cell differentiation and survival. Curr. Opin. Immunol. 20, 162-169 (2008).
10. Oracki, S.A., Walker, J.A., Hibbs, M.L., Corcoran, L.M. & Tarlinton, D.M. Plasma cell development and survival. Immunol. Rev. 237, 140-159 (2010).
11. Smith, K.G., Hewitson, T.D., Nossal, G.J. & Tarlinton, D.M. The phenotype and fate of the antibody-forming cells of the splenic foci. Eur. J. Immunol. 26, 444-448 (1996).
12. O'Connor, B.P. et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J. Exp. Med. 199, 91-98 (2004).
13. Benson, M.J. et al. Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J. Immunol. 180, 3655-3659 (2008).
14. Cassese, G. et al. Plasma cell survival is mediated by synergistic effects of cytokines and adhesion-dependent signals. J. Immunol. 171, 1684-1690 (2003).
15. Rodriguez Gomez, M. et al. Basophils support the survival of plasma cells in mice. J. Immunol. 185, 7180-7185 (2010).
16. Rozanski, C.H. et al. Sustained antibody responses depend on CD28 function in bone marrow-resident plasma cells. J. Exp. Med. 208, 1435-1446 (2011).
17. Tokoyoda, K., Egawa, T., Sugiyama, T., Choi, B.I. & Nagasawa, T. Cellular niches controlling B lymphocyte behavior within bone marrow during development. Immunity 20, 707-718 (2004).
18. Le Gouill, S., Podar, K., Harousseau, J.L. & Anderson, K.C. Mcl-1 regulation and its role in multiple myeloma. Cell Cycle 3, 1259-1262 (2004).
19. Potter, M. Neoplastic development in plasma cells. Immunol. Rev. 194, 177-195 (2003).
20. Belnoue, E. et al. APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells. Blood 111, 2755-2764 (2008).
21. Moreaux, J. et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 103, 3148-3157 (2004).
22. Carrington, E.M. et al. BH3 mimetics antagonizing restricted prosurvival Bcl-2 proteins represent another class of selective immune modulatory drugs. Proc. Natl. Acad. Sci. USA 107, 10967-10971 (2010).
23. Mérino, D. et al. Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells. Blood 119, 5807-5816 (2012).
24. Vikstrom, I. et al. Mcl-1 is essential for germinal center formation and B cell memory. Science 330, 1095-1099 (2010).
25. Tarte, K. et al. The Bcl-2 family member Bfl-1/A1 is strongly repressed in normal and malignant plasma cells but is a potent anti-apoptotic factor for myeloma cells. Br. J. Haematol. 125, 373-382 (2004).
26. Tangye, S.G. Staying alive: regulation of plasma cell survival. Trends Immunol. 32, 595-602 (2011).
27. Jiang, C., Loo, W.M., Greenley, E.J., Tung, K.S. & Erickson, L.D. B cell maturation antigen deficiency exacerbates lymphoproliferation and autoimmunity in murine lupus. J. Immunol. 186, 6136-6147 (2011).
28. Good, K.L., Avery, D.T. & Tangye, S.G. Resting human memory B cells are intrinsically programmed for enhanced survival and responsiveness to diverse stimuli compared to naive B cells. J. Immunol. 182, 890-901 (2009).
29. Glaser, S.P. et al. Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev. 26, 120-125 (2012).
30. Nojima, T. et al. In vitro derived germinal centre B cells differentially generate memory B or plasma cells in vivo. Nat. Commun. 2, 465 (2011).
31. Vieira, P. & Rajewsky, K. The half-lives of serum immunoglobulins in adult mice. Eur. J. Immunol. 18, 313-316 (1988).
32. Amanna, I.J., Carlson, N.E. & Slifka, M.K. Duration of humoral immunity to common viral and vaccine antigens. N. Engl. J. Med. 357, 1903-1915 (2007).
33. Hammarlund, E. et al. Duration of antiviral immunity after smallpox vaccination. Nat. Med. 9, 1131-1137 (2003).
34. Crotty, S. et al. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J. Immunol. 171, 4969-4973 (2003).
35. Radbruch, A. et al. Competence and competition: the challenge of becoming a long-lived plasma cell. Nat. Rev. Immunol. 6, 741-750 (2006).
36. Chu, V.T. et al. Eosinophils are required for the maintenance of plasma cells in the bone marrow. Nat. Immunol. 12, 151-159 (2011).
37. Mohr, E. et al. Dendritic cells and monocyte/macrophages that create the IL-6/APRIL-rich lymph node microenvironments where plasmablasts mature. J. Immunol. 182, 2113-2123 (2009).
38. Huard, B. et al. APRIL secreted by neutrophils binds to heparan sulfate proteoglycans to create plasma cell niches in human mucosa. J. Clin. Invest. 118, 2887-2895 (2008).
39. Sciammas, R. et al. Graded expression of interferon regulatory factor-4 coordinates isotype switching with plasma cell differentiation. Immunity 25, 225-236 (2006).
40. Shaffer, A.L. et al. IRF4 addiction in multiple myeloma. Nature 454, 226-231 (2008).
41. Manz, R.A., Hauser, A.E., Hiepe, F. & Radbruch, A. Maintenance of serum antibody levels. Annu. Rev. Immunol. 23, 367-386 (2005).
42. Novak, A.J. et al. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood 103, 689-694 (2004).
43. Tangye, S.G., Bryant, V.L., Cuss, A.K. & Good, K.L. BAFF, APRIL and human B cell disorders. Semin. Immunol. 18, 305-317 (2006).
44. Wuillème-Toumi, S. et al. Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia 19, 1248-1252 (2005).
45. van Vollenhoven, R.F., Kinnman, N., Vincent, E., Wax, S. & Bathon, J. Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo-controlled trial. Arthritis Rheum. 63, 1782-1792 (2011).
46. Genovese, M.C., Kinnman, N., de La Bourdonnaye, G., Pena Rossi, C. & Tak, P.P. Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a phase II, randomized, placebo-controlled, dose-finding trial. Arthritis Rheum. 63, 1793-1803 (2011).
47. Kopf, M. et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 368, 339-342 (1994).
48. Borriello, F. et al. B7-1 and B7-2 have overlapping, critical roles in immunoglobulin class switching and germinal center formation. Immunity 6, 303-313 (1997).
49. Kitamura, D., Roes, J., Kuhn, R. & Rajewsky, K.A. B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene. Nature 350, 423-426 (1991).
50. Janas, M.L., Hodgkin, P., Hibbs, M. & Tarlinton, D. Genetic evidence for Lyn as a negative regulator of IL-4 signaling. J. Immunol. 163, 4192-4198 (1999).